Your support fuels our research to #EndALS! Donate Now


TDI 207

This small molecule is being tested by scientists at the ALS Therapy Development Institute for its potential to help support the unfolded protein response in ALS patients. 


Type: Small Molecule
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

Since adding it in January of 2015, we've been able to rapidly move this compound into efficacy testing in SOD1 mice. We are hopeful it will show promise as a treatment for ALS.

Comment on this Topic

(All comments are moderated before they appear here.)